There is still a long way to go, at least 5 years, if they can make it work, not holding my breath for it.
If Japan comes on board by mid year, then they should be cash flow neutral at least, by the end of the year.
The big one is Vitiligo, which looks to be mid to late next year.
@Melody432 There is no doubt Perry's strategy has always been to go long, he said it to me at the 2019 AGM.
Ann: AVITA Medical Establishes Proof of Concept for Gene Therapy, page-17
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$3.07 |
Change
0.170(5.86%) |
Mkt cap ! $209.0M | |||
| Open | High | Low | Value | Volume |
| $3.04 | $3.10 | $3.04 | $1.789M | 583.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 13407 | $3.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $3.08 | 2746 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |